Live Ancillary Symposium: Hypophosphatemia: Unlocking the Key to Improved Diagnosis and Management

This program is a 60-minute virtual symposium including live Q&A that will take place on Friday, September 11, 2:30 - 3:30 pm Eastern Time and be available on-demand on Endocrine Society's Center for Learning platform. 

This program was funded through educational grants from Ultragenyx Pharmaceuticals. 

The live ancillary symposium and recording will include a pre-survey, post-assessment, evaluation, and follow-up survey, and will be certified for up to 1 AMA PRA Category 1 Credit and 1 ABIM MOC Point.

Learning Objectives

  • Evaluate the pros and cons of different imaging techniques for identifying tumor-induced osteomalacia
  • Identify symptoms to encourage evaluation for phosphorous management
  • Discuss optimal approaches to XLH management

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Activity summary
Available credit: 
  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
09/11/2020
Course expires: 
12/31/2020
Rating: 
0

Program

The clinical program will focus on clinical presentations on the state of care, challenges, and emerging therapies of Hypophosphatemia.

  • X-linked Hypophosphatemia Update: History and Future Goals of Treatment
  • Tumor-Induced Osteomalacia Diagnosis and Imaging
  • Tumor-Induced Osteomalacia Management and Therapeutic Goals
  • Patient Perspective
  • Audience Q&A with Patient and Expert Faculty
Co-Chairs:

Michael A. Levine, MD
Chief Emeritus, Endo & Diabetes
Children's Hosp of Philadelphia
Philadelphia, PA

Leanne M. Ward, MD
Tier 1 Research Chair in Pediatric Bone Disorders
Professor of Pediatrics, University of Ottawa
Medical Director, The CHEO Genetic and Metabolic Bone Disease Clinic
Scientific Director, The Ottawa Pediatric Bone Health Research Group
Pediatric Endocrinologist, Division of Endocrinology and Metabolism
Children's Hospital of Eastern Ontario
Ottawa, Ontario 

STATEMENT OF INDEPENDENCE

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Michael A. Levine, MD: Investigator, Ultragenyx Pharmaceuticals
  • Leanne M. Ward, MD : Clinical Trials, Ultragenyx Pharmaceuticals; Consultant, Ultragenyx Pharmaceuticals

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Deborah Sellmeyer, MD

The following SPC Committee members reported relevant financial relationships:
Andjela T. Drincic, MD: Advisory Board Member, Corcept
Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences
Amy Rothberg, MD: Spouse, consultant of Merck

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Katherine Araque, MD; Beret Ann Casey, MD; Jenny Blau, MD; Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

 

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMER

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment: 
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available. 
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

COMMERCIAL SUPPORT

This program was funded through educational grants from Ultragenyx Pharmaceuticals. 

Click "Start" to complete the meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.  

The Endocrine Society designates each webinar will to be certified for up to 1 AMA PRA Category 1 Credits and 1 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact. 

MAINTENANCE OF CERTIFICATION 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program, for each webinar. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

REVIEW YOUR DIPLOMATE ABIM ID NUMBER(S)
In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):
    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.
     
  2. Update Profile

Available Credit

  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation